Država: Kanada
Jezik: angleščina
Source: Health Canada
DIPYRIDAMOLE
GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE
B01AC07
DIPYRIDAMOLE
5MG
SOLUTION
DIPYRIDAMOLE 5MG
INTRAVENOUS
15G/50G
Prescription
MISCELLANEOUS VASODILATATING AGENTS
Active ingredient group (AIG) number: 0106621005; AHFS:
APPROVED
2020-11-30
_ _ _PERSANTINE Dipyridamole_ _ _ _Product Monograph_ _ _ _Page 1 of 27 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PERSANTINE ® Dipyridamole for Injection Solution, 5 mg/mL, intravenous Coronary Vasodilator Inhibitor of Platelet Adhesion and Aggregation Manufactured by: Glenwood GmbH Pharmazeutische Erzeugnisse Arabellastr. 17 81925 Munich Germany Date of Initial Authorization: Aug 30, 1960 Date of Revision: October 31, 2023 Imported by: McKesson Specialized Distribution Inc. 8449 Lawson Rd, Unit 102 Milton, Ontario L9T 9L1 Submission Control Number: 276658 _ _ _PERSANTINE Dipyridamole Product Monograph _ _Page 2 of 27 _ RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 PEDIATRICS .................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 4 4.1 DOSING CONSIDERATIONS ................................................................................................ 4 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT ........................................................... 4 4.3 RECONSTITUTION ......................... Preberite celoten dokument